Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Farther Finance Advisors LLC

Farther Finance Advisors LLC raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 620.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,505 shares of the biopharmaceutical company's stock after acquiring an additional 4,741 shares during the quarter. Farther Finance Advisors LLC's holdings in Halozyme Therapeutics were worth $341,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Halozyme Therapeutics by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after buying an additional 386,618 shares in the last quarter. Snyder Capital Management L P grew its holdings in shares of Halozyme Therapeutics by 2.6% during the 4th quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company's stock worth $199,294,000 after purchasing an additional 105,086 shares during the period. Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 8.8% during the 1st quarter. Congress Asset Management Co. now owns 2,132,707 shares of the biopharmaceutical company's stock worth $136,088,000 after acquiring an additional 172,971 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Halozyme Therapeutics by 2.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company's stock worth $92,446,000 after acquiring an additional 47,795 shares in the last quarter. Finally, Northern Trust Corp raised its position in Halozyme Therapeutics by 8.7% in the 4th quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company's stock valued at $87,386,000 after purchasing an additional 145,617 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Down 1.5%

Shares of NASDAQ:HALO opened at $53.11 on Wednesday. The stock has a market capitalization of $6.54 billion, a P/E ratio of 14.13, a PEG ratio of 0.36 and a beta of 1.19. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $70.51. The stock has a 50-day simple moving average of $57.12 and a 200-day simple moving average of $56.20. The company has a debt-to-equity ratio of 3.13, a quick ratio of 7.30 and a current ratio of 8.39.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. The firm had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. Halozyme Therapeutics's quarterly revenue was up 35.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.79 EPS. Equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Wall Street Analyst Weigh In

HALO has been the topic of a number of research reports. Morgan Stanley downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $73.00 to $62.00 in a research note on Wednesday, May 14th. Benchmark cut Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, May 29th. JPMorgan Chase & Co. boosted their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Finally, Leerink Partnrs downgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Hold" and a consensus price target of $61.90.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 4,497 shares of the company's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the sale, the director now directly owns 28,611 shares of the company's stock, valued at approximately $1,727,246.07. This represents a 13.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.90% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.